⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16914444 | 1.00 | — | — | |
| SCHEMBL19717649 | 1.00 | — | — | |
| SCHEMBL16925393 | 0.85 | GPR119 (0.37) | — | |
| SCHEMBL30929681 | 0.85 | GPR119 (0.37) | — | |
| SCHEMBL19641350 | 0.85 | GPR119 (0.37) | — | |
| SCHEMBL20337420 | 0.81 | NAMPT (0.32) | — | |
| SCHEMBL20337421 | 0.81 | NAMPT (0.32) | — | |
| SCHEMBL21631730 | 0.78 | — | — | |
| SCHEMBL20954117 | 0.78 | — | — | |
| SCHEMBL20954116 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199609-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2024-06-20 | — | — | US | disclosed |
| US-20210300919-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2021-09-30 | — | — | US | disclosed |
| US-10934285-B2 | Compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2021-03-02 | — | — | US | disclosed |
| EP-3468972-B1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2020-05-20 | — | — | EP | disclosed |
| EP-3468972-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2019-04-17 | — | — | EP | disclosed |
| WO-2017216706-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2017-12-21 | — | — | WO | disclosed |